CCRM, OmniaBio, and Avectas Collaborate to Automate and Scale Cell Therapy Manufacturing

PR Newswire Canada

Overview

CCRM and its CDMO subsidiary OmniaBio Inc. have partnered with Avectas Limited to evaluate and integrate Avectas’ automated, scalable cell therapy manufacturing platform. This collaboration aims to enhance consistency, scale-up capabilities, and cost-effectiveness in cell therapy production, critical for immune cell-based, iPSC, CAR-T, and lentiviral vector therapies. The initiative is set to accelerate the commercialization of advanced regenerative medicines and broaden patient access.

In Depth

Key Findings

CCRM and its contract development and manufacturing organization (CDMO) subsidiary, OmniaBio Inc., have announced a strategic partnership with Avectas Limited. The collaboration focuses on evaluating and implementing Avectas’ automated, integrated, and scalable manufacturing platform for cell therapies. This initiative is designed to address key challenges in cell therapy production, specifically enhancing process consistency, improving scale-up capabilities, and achieving greater cost-effectiveness.

Technical / Clinical Details

• Avectas Platform: Avectas’ technology offers an automated and integrated solution for cell therapy manufacturing. This minimizes manual intervention, reduces the risk of human error and contamination, and ensures higher batch-to-batch consistency.
• OmniaBio’s Expertise: OmniaBio specializes in the manufacturing of immune cell-based therapies, induced pluripotent stem cell (iPSC) therapies, CAR-T cell products, and lentiviral vectors. By integrating Avectas’ automation into its existing specialized workflows, OmniaBio aims to provide more efficient and scalable solutions for complex cell therapy products.
• Addressing Industry Bottlenecks: The primary hurdles for cell therapy commercialization include complex manufacturing processes, high production costs, and difficulties in scaling up. This partnership directly targets these issues, seeking to streamline production to make these life-saving therapies accessible to a wider patient population.

Background & Context

The field of regenerative medicine and cell therapy is rapidly advancing, yet manufacturing capacity and cost remain significant constraints in transitioning therapies from research to clinical and commercial production. Traditional manufacturing methods are often labor-intensive, manual, and prone to variability and contamination. CCRM and OmniaBio play a crucial role in strengthening the cell therapy manufacturing ecosystem in Canada, and partnerships like this with Avectas are vital for improving overall industry manufacturing capabilities.

Strategic Significance & Outlook

A successful implementation of this partnership is expected to dramatically enhance the efficiency of cell therapy manufacturing, facilitating faster clinical development and commercialization. Furthermore, reduced manufacturing costs could lead to more affordable cell therapies, increasing patient access to these innovative treatments. In the long term, such automated and integrated manufacturing platforms are poised to become standard practices in the cell and gene therapy sector, accelerating the development and widespread adoption of new therapeutic modalities globally. This collaboration underscores the industry’s collective effort to mature manufacturing processes to meet escalating demand and unlock the full potential of advanced therapies.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime